Log in
Enquire now
‌

US Patent 7521205 Genes and polypeptides relating to prostate cancers

Patent 7521205 was granted and assigned to OncoTherapy Science, Inc. on April, 2009 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent
0

Patent attributes

Current Assignee
OncoTherapy Science, Inc.
OncoTherapy Science, Inc.
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
75212050
Patent Inventor Names
Hidewaki Nakagawa0
Yusuke Nakamura0
Toyomasa Katagiri0
Shuichi Nakatsuru0
Date of Patent
April 21, 2009
0
Patent Application Number
105293810
Date Filed
September 22, 2003
0
Patent Primary Examiner
‌
Stephen L. Rawlings
0
Patent abstract

The present application provides novel human gene MICAL2-PV whose expression is markedly elevated in prostate cancers. Furthermore, it provides polypeptides encoded by the gene as well as polypeptides encoded by PCOTH which expression was also discovered to be elevated in prostate cancers. The genes and polypeptides encoded by the genes can be used, for example, in the diagnosis of prostate cancers, as target molecules for developing drugs against the disease, and for attenuating cell growth of prostate cancer.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 7521205 Genes and polypeptides relating to prostate cancers

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.